Positive News SentimentPositive NewsNASDAQ:ITOS iTeos Therapeutics (ITOS) Stock Price, News & Analysis $17.21 +0.50 (+2.99%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$16.73▼$17.4150-Day Range$14.02▼$18.0952-Week Range$8.20▼$18.75Volume180,436 shsAverage Volume351,553 shsMarket Capitalization$621.63 millionP/E RatioN/ADividend YieldN/APrice Target$32.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get iTeos Therapeutics alerts: Email Address iTeos Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside85.9% Upside$32.00 Price TargetShort InterestBearish9.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.62Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($4.57) to ($5.76) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.02 out of 5 starsMedical Sector638th out of 936 stocksBiological Products, Except Diagnostic Industry104th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingiTeos Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageiTeos Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about iTeos Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.50% of the float of iTeos Therapeutics has been sold short.Short Interest Ratio / Days to CoveriTeos Therapeutics has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in iTeos Therapeutics has recently increased by 1.15%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldiTeos Therapeutics does not currently pay a dividend.Dividend GrowthiTeos Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ITOS. Previous Next 3.7 News and Social Media Coverage News SentimentiTeos Therapeutics has a news sentiment score of 1.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for iTeos Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ITOS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added iTeos Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, iTeos Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.50% of the stock of iTeos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.16% of the stock of iTeos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about iTeos Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for iTeos Therapeutics are expected to decrease in the coming year, from ($4.57) to ($5.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of iTeos Therapeutics is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of iTeos Therapeutics is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioiTeos Therapeutics has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about iTeos Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840. Click here to see the details because there’s not much time to prepare. About iTeos Therapeutics Stock (NASDAQ:ITOS)Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.Read More ITOS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ITOS Stock News HeadlinesJuly 22, 2024 | americanbankingnews.comiTeos Therapeutics (NASDAQ:ITOS) Shares Gap Up to $15.73July 8, 2024 | seekingalpha.comiTeos Therapeutics: Rippling Waves Of TIGIT PessimismJuly 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."July 8, 2024 | globenewswire.comiTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSKJune 17, 2024 | globenewswire.comiTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung CancerMay 10, 2024 | marketwatch.comITeos Therapeutics Shares Surge 47% After Promising Tumor Treatment DataMay 10, 2024 | finanznachrichten.deiTeos Therapeutics Inc.: iTeos Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 10, 2024 | finanznachrichten.deiTeos Therapeutics Inc.: iTeos Therapeutics Announces $120 Million Registered Direct OfferingJuly 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."May 10, 2024 | globenewswire.comiTeos Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 10, 2024 | globenewswire.comiTeos Therapeutics Announces $120 Million Registered Direct OfferingMay 6, 2024 | seekingalpha.comADC Therapeutics Non-GAAP EPS of -$0.38, revenue of $17.8M misses by $0.32MApril 16, 2024 | investing.comIteos Therapeutics Inc (ITOS)April 7, 2024 | globenewswire.comiTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024March 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: iTeos Therapeutics (ITOS), Rani Therapeutics Holdings (RANI) and Vor Biopharma (VOR)March 11, 2024 | finance.yahoo.comITOS Oct 2024 17.000 callMarch 11, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: iTeos Therapeutics (ITOS), Viracta Therapeutics (VIRX)March 10, 2024 | finance.yahoo.comITOS Oct 2024 12.000 callSee More Headlines Receive ITOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ITOS CUSIPN/A CIK1808865 Webwww.iteostherapeutics.com Phone339-217-0161FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$32.00 High Stock Price Target$46.00 Low Stock Price Target$21.00 Potential Upside/Downside+85.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,640,000.00 Net MarginsN/A Pretax Margin-865.66% Return on Equity-23.15% Return on Assets-20.20% Debt Debt-to-Equity RatioN/A Current Ratio13.51 Quick Ratio13.51 Sales & Book Value Annual Sales$12.60 million Price / Sales49.34 Cash FlowN/A Price / Cash FlowN/A Book Value$16.08 per share Price / Book1.07Miscellaneous Outstanding Shares36,120,000Free Float31,608,000Market Cap$621.63 million OptionableOptionable Beta1.40 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Michel Detheux Ph.D. (Age 57)President, CEO & Director Comp: $1.04MMr. Matthew Gall (Age 47)Chief Financial Officer Comp: $648kMr. Matthew A. Call M.B.A. (Age 51)Chief Operating Officer Comp: $706.21kDr. Yvonne McGrath Ph.D. (Age 50)Chief Scientific Officer Ms. Adi OsovskyExecutive Vice President of LegalMr. Philippe BrantegemExecutive Vice President of Human ResourcesDr. Joyson Joseph Karakunnel FACP (Age 53)M.D., M.Sc., Interim Chief Medical Officer More ExecutivesKey CompetitorsNantKwestNASDAQ:NKVaxartNASDAQ:VXRTNovavaxNASDAQ:NVAXCG OncologyNASDAQ:CGONRecursion PharmaceuticalsNASDAQ:RXRXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 5,409 shares on 7/26/2024Ownership: 0.336%Allspring Global Investments Holdings LLCSold 5,991 shares on 7/26/2024Ownership: 0.010%Ikarian Capital LLCSold 245,146 shares on 5/17/2024Ownership: 0.281%Jacobs Levy Equity Management Inc.Sold 30,116 shares on 5/16/2024Ownership: 1.397%California State Teachers Retirement SystemSold 1,387 shares on 5/16/2024Ownership: 0.065%View All Insider TransactionsView All Institutional Transactions ITOS Stock Analysis - Frequently Asked Questions How have ITOS shares performed this year? iTeos Therapeutics' stock was trading at $10.95 at the beginning of 2024. Since then, ITOS stock has increased by 57.2% and is now trading at $17.21. View the best growth stocks for 2024 here. How were iTeos Therapeutics' earnings last quarter? iTeos Therapeutics, Inc. (NASDAQ:ITOS) issued its quarterly earnings data on Friday, May, 10th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.02) by $0.05. When did iTeos Therapeutics IPO? iTeos Therapeutics (ITOS) raised $151 million in an IPO on Friday, July 24th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are iTeos Therapeutics' major shareholders? Top institutional shareholders of iTeos Therapeutics include Bank of New York Mellon Corp (0.34%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Boxer Capital, Llc, Michel Detheux, Matthew Gall, Bioventures 2018 LP Mpm, Bioventures 2014 LP Mpm, Detlev Biniszkiewicz, David Hallal, Joanne Jenkins Lager, Ansbert Gadicke and Yvonne Mcgrath. View institutional ownership trends. How do I buy shares of iTeos Therapeutics? Shares of ITOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of iTeos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that iTeos Therapeutics investors own include Advanced Micro Devices (AMD), GW Pharmaceuticals (GWPH), Trevena (TRVN), Blink Charging (BLNK), Chegg (CHGG) and Centene (CNC). This page (NASDAQ:ITOS) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iTeos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ITOS Stock Alerts